Home >> Top News >> Quest acquires Seattle-based PhenoPath

Quest acquires Seattle-based PhenoPath

Print Friendly, PDF & Email

Oct. 17, 2018—Quest Diagnostics announced it has acquired PhenoPath, a national provider of specialized anatomic pathology and related services.

Based in Seattle, PhenoPath provides AP, molecular oncology, and other services that complement and extend those of the company’s advanced diagnostics portfolio of services such as genetic sequencing and genomic tumor analysis.

“Our acquisition of PhenoPath delivers on our accelerate growth strategy for advanced diagnostics,” Steve Rusckowski, chairman, president, and CEO of Quest Diagnostics, said in a statement. “PhenoPath has a strong record of innovation and provides several capabilities that complement and extend our own, particularly in pathology and molecular oncology. It also deepens our presence in the Pacific Northwest.”

The PhenoPath business will operate as part of AmeriPath, a wholly owned business of Quest. AmeriPath provides pathology services to ambulatory health and surgery centers, imaging centers, clinics, and physician offices, and has on-site community pathologists in more than 170 hospitals across the country.

x

Check Also

Veracyte, Quest agreement, 5/17

May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.

X